About ArriVent BioPharma, Inc. Common Stock
https://www.arrivent.comArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors.
CEO
Zhengbin Yao
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 94
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
HHLR ADVISORS, LTD.
Shares:4.48M
Value:$100.77M
INFINITUM ASSET MANAGEMENT, LLC
Shares:3.87M
Value:$86.93M
SUVRETTA CAPITAL MANAGEMENT, LLC
Shares:3.7M
Value:$83.22M
Summary
Showing Top 3 of 110
About ArriVent BioPharma, Inc. Common Stock
https://www.arrivent.comArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $38.32M ▲ | $-34.98M ▼ | 0% | $-0.83 ▲ | $-34.98M ▼ |
| Q2-2025 | $0 | $33.62M ▼ | $-31.4M ▲ | 0% | $-0.9 ▲ | $-31.4M ▲ |
| Q1-2025 | $0 | $66.77M ▲ | $-64.39M ▼ | 0% | $-1.9 ▼ | $-66.77M ▼ |
| Q4-2024 | $0 | $23.7M ▼ | $-20.63M ▼ | 0% | $-0.61 | $-23.7M ▲ |
| Q3-2024 | $0 | $24.23M | $-20.56M | 0% | $-0.61 | $-24.23M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $300.27M ▲ | $326.56M ▲ | $21.56M ▲ | $305M ▲ |
| Q2-2025 | $235.69M ▲ | $269.51M ▲ | $19.64M ▲ | $249.87M ▲ |
| Q1-2025 | $176.08M ▼ | $215.5M ▼ | $12.95M ▼ | $202.54M ▼ |
| Q4-2024 | $218.86M ▼ | $274.94M ▼ | $17.29M ▲ | $257.65M ▼ |
| Q3-2024 | $282.86M | $292.71M | $15.22M | $277.49M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-34.98M ▼ | $-35.8M ▼ | $-50.76M ▼ | $86.47M ▲ | $-93K ▼ | $-35.8M ▼ |
| Q2-2025 | $-31.4M ▲ | $-26.12M ▲ | $13.91M ▼ | $75.11M ▲ | $62.9M ▲ | $-26.12M ▲ |
| Q1-2025 | $-64.39M ▼ | $-68.01M ▼ | $36.82M ▲ | $6.76M ▲ | $-24.43M ▲ | $-68.01M ▼ |
| Q4-2024 | $-20.63M ▼ | $-16.15M ▲ | $-192.47M ▼ | $55K ▼ | $-208.56M ▼ | $-16.15M ▲ |
| Q3-2024 | $-20.56M | $-16.34M | $0 | $531K | $-15.81M | $-16.34M |
CEO
Zhengbin Yao
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 94
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
HHLR ADVISORS, LTD.
Shares:4.48M
Value:$100.77M
INFINITUM ASSET MANAGEMENT, LLC
Shares:3.87M
Value:$86.93M
SUVRETTA CAPITAL MANAGEMENT, LLC
Shares:3.7M
Value:$83.22M
Summary
Showing Top 3 of 110